FATE THERAPEUTICS INC Proceeds from Common Stock Issued
FATE THERAPEUTICS INC (FATE) reported Proceeds from Common Stock Issued of -$104.00 thousand for the 3-month period ending 2024-06-30, per its 10-Q filed 2025-11-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2025-11-13
- FATE THERAPEUTICS INC proceeds from issuance of common stock for the quarter ending 2024-06-30 was -$104.00K.
- FATE THERAPEUTICS INC proceeds from issuance of common stock for the quarter ending 2024-03-31 was $74.64M.
- FATE THERAPEUTICS INC proceeds from issuance of common stock for the quarter ending 2021-12-31 was -$31.00K.
- FATE THERAPEUTICS INC proceeds from issuance of common stock for the quarter ending 2021-09-30 was $0.00.
- FATE THERAPEUTICS INC proceeds from issuance of common stock for fiscal 2021 was $411.74M, a 118.10% increase from fiscal 2020.
- FATE THERAPEUTICS INC proceeds from issuance of common stock for fiscal 2020 was $188.78M, a 16.24% increase from fiscal 2019.
- FATE THERAPEUTICS INC proceeds from issuance of common stock for fiscal 2019 was $162.41M, a 20.68% increase from fiscal 2018.
- FATE THERAPEUTICS INC proceeds from issuance of common stock for fiscal 2018 was $134.58M, a 211.48% increase from fiscal 2017.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month | Proceeds from Issuance of Common Stock 80 month | Proceeds from Issuance of Common Stock 83 month |
|---|---|---|---|---|---|---|
| 2024-06-30 | -$104.00K 10-Q · filed 2025-11-13 | $74.53M derived: sum of 2 quarters · filed 2025-11-13 | ||||
| 2024-03-31 | $74.64M 10-Q · filed 2025-11-13 | |||||
| 2021-12-31 | -$31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$31.00K derived: sum of 2 quarters · filed 2022-02-28 | $411.74M 10-K · filed 2022-02-28 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $411.77M 10-Q · filed 2021-11-04 | ||||
| 2021-06-30 | $411.77M 10-Q · filed 2021-08-04 | |||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$270.00K derived: sum of 2 quarters · filed 2022-02-28 | $188.78M 10-K · filed 2022-02-28 | |||
| 2020-09-30 | -$270.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $188.78M 10-Q · filed 2021-11-04 | ||||
| 2020-06-30 | $189.05M 10-Q · filed 2021-08-04 | |||||
| 2019-12-31 | -$136.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $162.41M 10-K · filed 2022-02-28 | ||||
| 2019-09-30 | $162.54M 10-Q · filed 2020-11-05 | |||||
| 2018-12-31 | -$245.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $134.58M 10-K · filed 2021-02-24 | ||||
| 2018-09-30 | $134.82M 10-Q · filed 2019-11-05 | |||||
| 2017-12-31 | $43.21M 10-K · filed 2020-03-02 | |||||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | $0.00 derived: sum of 2 quarters · filed 2018-03-05 | $4.50M derived: sum of 3 quarters · filed 2018-03-05 | $4.58M 10-K · filed 2018-03-05 | ||
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $4.50M derived: sum of 2 quarters · filed 2016-11-07 | $4.58M 10-Q · filed 2016-11-07 | $4.58M derived: sum of 4 quarters · filed 2016-11-07 | ||
| 2015-06-30 | $4.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $4.58M 10-Q · filed 2016-08-08 | $4.58M derived: sum of 3 quarters · filed 2016-08-08 | $4.58M derived: sum of 4 quarters · filed 2016-08-08 | ||
| 2015-03-31 | $75.00K 10-Q · filed 2015-05-07 | $71.00K derived: sum of 2 quarters · filed 2015-05-07 | $73.00K derived: sum of 3 quarters · filed 2015-05-07 | $219.00K derived: sum of 4 quarters · filed 2015-05-07 | ||
| 2014-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | -$2.00K derived: sum of 2 quarters · filed 2015-03-12 | $144.00K derived: sum of 3 quarters · filed 2015-03-12 | $142.00K 10-K · filed 2015-03-12 | ||
| 2014-09-30 | $2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $148.00K derived: sum of 2 quarters · filed 2014-11-12 | $146.00K 10-Q · filed 2014-11-12 | $146.00K derived: sum of 4 quarters · filed 2015-05-07 | ||
| 2014-06-30 | $146.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | $144.00K 10-Q · filed 2014-08-12 | $144.00K derived: sum of 3 quarters · filed 2015-05-07 | $166.00K derived: sum of 4 quarters · filed 2015-05-07 | ||
| 2014-03-31 | -$2.00K 10-Q · filed 2015-05-07 | -$2.00K derived: sum of 2 quarters · filed 2015-05-07 | $20.00K derived: sum of 3 quarters · filed 2015-05-07 | $292.00K 10-Q · filed 2014-05-13 | ||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $22.00K derived: sum of 2 quarters · filed 2015-03-12 | $23.00K 10-K · filed 2015-03-12 | $294.00K 10-K · filed 2014-03-17 | ||
| 2013-09-30 | $22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $23.00K 10-Q · filed 2014-11-12 | ||||
| 2013-06-30 | $1.00K 10-Q · filed 2014-08-12 | |||||
| 2012-12-31 | $207.00K 10-K · filed 2015-03-12 | |||||
| 2011-12-31 | $14.00K 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |